June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and patient well-being.

The combination of trastuzumab deruxtecan (T-DXd; Enhertu) and pertuzumab (Perjeta) extended progression-free survival (PFS) by nearly 14 months compared with the current first-line standard of care.

Rates of HER2 expression are examined and trastuzumab is tested in combination with paclitaxel and carboplatin in patients with resistant advanced ovarian cancer.

In a large Chinese trial presented at the American Society of Clinical Oncology annual meeting, neoadjuvant therapy with a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta) in combination ...